Intellia Therapeutics (NTLA) Operating Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Operating Expenses data on file, last reported at $115.6 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $115.6 million, down 15.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $486.8 million (down 17.02% YoY), and the FY2025 annual result was $508.7 million, down 14.1% from the prior year.
• Operating Expenses slipped to $115.6 million in Q1 2026 per NTLA's latest filing, from $121.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $155.5 million in Q1 2022 and troughed at $112.3 million in Q2 2022.
• A 5-year average of $134.0 million and a median of $137.4 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 194.11% in 2022, then dropped 19.89% in 2023.
• A 5-year view of Operating Expenses shows it stood at $123.7 million in 2022, then gained by 11.58% to $138.0 million in 2023, then grew by 8.22% to $149.3 million in 2024, then fell by 18.48% to $121.7 million in 2025, then fell by 5.05% to $115.6 million in 2026.
• Business Quant data shows NTLA's Operating Expenses at $115.6 million in Q1 2026, $121.7 million in Q4 2025, and $125.3 million in Q3 2025.